Seattle Genetics Highlights ADCETRISA (Brentuximab Vedotin) Data in...

Seattle Genetics Highlights ADCETRIS A Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting -Investigator Analysis Shows Median Overall Survival for ADCETRIS-Treated Relapsed HL Patients after ASCT Was 91 Months Compared with 28 Months among Non-ADCETRIS Patients- -ADCETRIS ... (more)

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20121210005426&newsLang=en&ndmConfigId=1000639&vnsId=41